These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38310626)

  • 1. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.
    Pelewicz K; Miśkiewicz P
    J Endocrinol Invest; 2024 Aug; 47(8):1987-1994. PubMed ID: 38310626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
    Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
    Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with Intravenous Methylprednisolone in Patients with Graves' Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate.
    Pelewicz K; Szewczyk S; Miśkiewicz P
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal reserve following treatment of Graves' orbitopathy with intravenous glucocorticoids.
    Giotaki Z; Fountas A; Tsirouki T; Bargiota A; Tigas S; Tsatsoulis A
    Thyroid; 2015 Apr; 25(4):462-3. PubMed ID: 25602127
    [No Abstract]   [Full Text] [Related]  

  • 5. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
    Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.
    Rymuza J; Popow M; Bednarczuk T; Miśkiewicz P
    Pol Merkur Lekarski; 2019 Sep; 47(279):91-94. PubMed ID: 31557136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
    Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
    Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
    Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
    J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study.
    Rymuza J; Pelewicz K; Przedlacki J; Miśkiewicz P
    Front Endocrinol (Lausanne); 2022; 13():893600. PubMed ID: 35909547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
    Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
    Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio.
    Siomkajło M; Mizera Ł; Szymczak D; Kolačkov K; Grzegrzółka J; Bolanowski M; Daroszewski J
    J Endocrinol Invest; 2021 Nov; 44(11):2475-2484. PubMed ID: 33866536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
    Park J; Kim J; Kim SS; Choi HY
    Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for thyroid-stimulating immunoglobulin normalization in moderate-to-severe Graves' orbitopathy: a 36-month longitudinal study.
    Park J; Son Y; Kim J; Kim S; Choi HY
    BMC Ophthalmol; 2024 Aug; 24(1):361. PubMed ID: 39169342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
    Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
    Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
    Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
    Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
    [No Abstract]   [Full Text] [Related]  

  • 17. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
    Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
    Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.
    Rymuza J; Gutowska K; Kurpios-Piec D; Struga M; Miśkiewicz P
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.